### AGENDA
Thursday, November 11, 2022

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM</td>
<td>Registration</td>
<td></td>
</tr>
<tr>
<td>8:00 AM</td>
<td>Welcome</td>
<td>R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)</td>
</tr>
<tr>
<td>8:10 AM</td>
<td>Symposium Introduction</td>
<td>Ashrith Guha, MD, MPH FACC</td>
</tr>
</tbody>
</table>

**Plenary Session I**
Moderators: Kelly H. Schlendorf, MD, Ju Kim, MD, Shelley Hall, MD, Annette Jackson, MD

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:17 AM</td>
<td>State-of-Art-Lecture I: Past, Present and Future</td>
<td>Mario Deng, MD, FACC, FESC</td>
</tr>
<tr>
<td>8:57 AM</td>
<td>Molecular Mechanisms acute rejection: Novel Insights</td>
<td>Xian Chang Li, MD, PhD</td>
</tr>
<tr>
<td>9:17 AM</td>
<td>Cell Free DNA - What does it add to diagnosing rejection</td>
<td>Shelley Hall, MD, FACC, FHFSA, FAST</td>
</tr>
<tr>
<td>9:37 AM</td>
<td>Question and Answer Discussion</td>
<td>Kelly H. Schlendorf, MD, Ju Kim, MD, Shelley Hall, MD, Annette Jackson, MD</td>
</tr>
<tr>
<td>9:52 AM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

**Plenary Session II**
Moderators: Mary Jane Farr, MD, Shelley Hall, MD, Imad Hussain, MD and Mario Deng, MD

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:07 AM</td>
<td>DSAs - Which are Important and What to do About Them?</td>
<td>Todd N. Eagar, PhD</td>
</tr>
<tr>
<td>10:27 AM</td>
<td>CMR/PET Imaging in Management of Rejection?</td>
<td>Dipan J. Shah, MD, FACC</td>
</tr>
<tr>
<td>10:47 AM</td>
<td>Non-HLA Antibodies? When do you Test and what to do About Them?</td>
<td>Annette Jackson, MD</td>
</tr>
<tr>
<td>11:07 AM</td>
<td>Managing Sensitized Patient Prior to Transplantation</td>
<td>Marlena Habal, MD, FRCPC</td>
</tr>
<tr>
<td>11:27 AM</td>
<td>Question and Answer Discussion</td>
<td>Mary Jane Farr, MD, Shelley Hall, MD, Imad Hussain, MD and Mario Deng, MD</td>
</tr>
<tr>
<td>11:42 AM</td>
<td>Lunch and Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

**Plenary Session III**
Moderators: Sepna Legha, MD, Mary Jane Farr, MD, Kelly Schlendorf, MD and Mahwash Kassi, MD

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:27 PM</td>
<td>Case Discussions</td>
<td>Case#1: Lauren Truby, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case#2: Sall Kumar, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case#3: Kelsey Patel, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Case#4: Matthew Riesbeck, MD</td>
</tr>
<tr>
<td>1:47 PM</td>
<td>Novel Immunosuppressive agents: Role in the Era of Generics</td>
<td>Alex Rogers, PharmD, BCPS</td>
</tr>
<tr>
<td>2:07 PM</td>
<td>Positive Crossmatch: Back to Cytotoxic crossmatch?</td>
<td>Annette M Jackson, PhD, F(ACHI)</td>
</tr>
<tr>
<td>2:27 PM</td>
<td>Question and Answer / Case Discussions – Putting it into Practice</td>
<td>Sepna Legha, MD, Mary Jane Farr, MD, Kelly Schlendorf, MD and Mahwash Kassi, MD</td>
</tr>
<tr>
<td>2:42 PM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
</tbody>
</table>

**Plenary Session IV**
Moderators: Rayan Yousefzai, MD, Mario Deng, MD, Annette Jackson, MD and Nadia Fida, MD

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:57 PM</td>
<td>DEBATE Immunosuppression: Tailoring Care or Standardizing Protocols for Better Outcomes</td>
<td>Kelly Schlendorf, MD</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mary Jane Farr, MD</td>
</tr>
<tr>
<td>3:37 PM</td>
<td>Rebuttal</td>
<td></td>
</tr>
</tbody>
</table>
Heart Symposium: Rejection of the Heart: New Frontiers in the Diagnosis and Treatment
Course Director: R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)
Friday, November 11, 2022 | Hybrid Symposium

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:47 PM</td>
<td>Role of Photopheresis in Rejection</td>
<td>Ashrith Guha, MD, MPH FACC</td>
</tr>
<tr>
<td>3:59 PM</td>
<td>Is There Chronic AMR in the Heart?</td>
<td>Arvind Bhimaraj, MD</td>
</tr>
<tr>
<td>4:11 PM</td>
<td>Rejection in Multi-Organ Transplantation</td>
<td>Cindy Martin, MD</td>
</tr>
<tr>
<td>4:23 PM</td>
<td>Biopsy Negative Rejection in the Current Era</td>
<td>Janardhana Rao Gorthi, MD</td>
</tr>
<tr>
<td>4:35 PM</td>
<td>Question and Answer Discussion</td>
<td>Rayan Yousefzai, MD, Mario Deng, MD, Annette Jackson, MD and Nadia Fida, MD</td>
</tr>
<tr>
<td>4:50 PM</td>
<td>Conclusion</td>
<td>Cindy Martin, MD</td>
</tr>
<tr>
<td>5:00 PM</td>
<td>Adjournment</td>
<td></td>
</tr>
</tbody>
</table>

FACULTY

COURSE DIRECTOR

R. Mark Ghobrial, MD, PhD, FACS, FRCS (Ed)

J.C. Walter Jr. Presidential Distinguished Chair
Director, J.C. Walter Jr. Transplant Center
Director, Transplantation Research
Chief, Division of Transplantation, Department of Surgery
Professor of Surgery
Weill Cornell Medical College
Houston Methodist

HOUSTON METHODIST FACULTY

Todd N. Eagar, PhD
Assistant Professor of Pathology and Genomic Medicine, Academic Institute
Assistant Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Ashrith Guha, MD, MPH FACC
Medical Director, Heart Transplant and MCS Program(JCWTC)
Director, Pulmonary Hypertension and Right Heart Failure Program(MDHAVC)
Assistant Professor of Cardiology, Houston Methodist Institute for Academic Medicine
Assistant Professor of Medicine, Weill Cornell Medical College
Houston Methodist Hospital

Xian Chang Li, MD, PhD
Max and Lillie Frosch Centennial Chair in Transplant Research, Immunobiology & Transplant Science Center
Professor of Transplant Immunology in Surgery, Academic Institute
Full Member, Research Institute
Director, Immunobiology & Transplant Science Center
Houston Methodist
Weill Cornell Medical College
Alex Rogers, PharmD, BCPS
Senior Pharmacy Clinical Specialist,
Solid Organ Transplant
Houston Methodist

Dipan J. Shah, MD, FACC
Beverly B. and Daniel C. Arnold Distinguished Centennial Chair, Department of Cardiology
Professor of Cardiology, Academic Institute
Full Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Rayan Yousefzai, MD
Assistant Professor of Cardiology, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College

GUEST FACULTY

Mario Deng, MD, FACC, FESC
Professor of Medicine
Advanced Heart Failure/Mechanical Support/Heart Transplant
David Geffen School of Medicine at UCLA
Ronald Reagan UCLA Medical Center
Santa Monica, California

Maryjane Farr, MD, MSc, FACC, FAST
Section Chief of Heart Failure, Mechanical Circulatory Support and Transplant
Jackie and Charles Solomon Distinguished Chair in Clinical Excellence
UT Southwestern Medical Center
Dallas, TX

Marlena Habal, MD, FRCPC
Assistant Professor of Medicine
NYU Grossman School of Medicine
NYU Langone
New York, NY
Shelley Hall, MD, FACC, FHFS, FAST
Chief, Department of Advanced Heart Failure, Mechanical Circulatory Support and Transplant
Annette C. and Harold C. Simmons Transplant Institute,
Baylor Scott & White Research Institute
Baylor University Medical Center
Dallas, TX

Annette M Jackson, PhD, F(ACHI)
Associate Professor in Surgery
Associate Professor in Immunology
Duke Surgery
Duke University School of Medicine

Kelly H. Schlendorf, MD, MHS
Director, Heart Failure and Transplant
Medical Director, Adult Heart Transplant Program
Assistant Professor of Medicine
Vanderbilt Health
Nashville, TN

MODERATORS

Imad Hussain, MD
Assistant Professor of Cardiology, Academic Institute
Assistant Clinical Member, Research Institute
Program Director, Advanced Heart Failure and Transplant Cardiology Fellowship, Department of Cardiology
Houston Methodist
Weill Cornell Medical College

Ju Kim, MD, FACC
Interim Medical Director, Cardiac Intensive Care Unit
Houston Methodist DeBakey Cardiology Associates
Assistant Professor of Cardiology, Academic Institute
Assistant Clinical Member, Research Institute
Houston Methodist
Weill Cornell Medical College

Kelly H. Schlendorf, MD, MHS
Director, Heart Failure and Transplant
Medical Director, Adult Heart Transplant Program
Assistant Professor of Medicine
MODERATORS

Salil Kumar, MD  
Medical Resident  
Houston Methodist

Kelsey Patel, MD  
Medical Resident  
Houston Methodist

Matthew Riesbeck, MD  
Medical Resident  
Baylor College of Medicine

Lauren Truby, MD  
Medical Resident  
UT Southwestern

PROGRAM OVERVIEW
The Houston Methodist J.C. Walter Jr. Transplant Center is proud to introduce its leading educational event of the year. This program is designed to provide an innovative view on strategies for the widespread issues of organ failure management. Renowned national and international speakers will share their state-of-the-art techniques and advanced research to educate attendees on the advancements of organ failure management.

TARGET AUDIENCE
The George P. Noon Conference Series is designed for nephrologists, cardiologists, gastroenterologists, hepatologists, pulmonologists, pathologists, internists, oncologists, physicians treating patients with organ failure, nurses, family practitioners, social workers and allied health professionals with an interest in organ failure transplant management.

EDUCATIONAL OBJECTIVES
Upon completion of this course, the participant should be able to:
- Analyze the past, present and future of heart rejection
- Distinguish the difference of tailoring care or standardizing Immunosuppression protocols for better outcomes
- Explain the relevance and management of positive Cross-match
- Indicate when to test for Non-HLA antibodies and what to do about them
- Assess the latest treatment options for heart failure management
- Deliberate the pros and cons of surgical and nonsurgical management of heart failure

NURSING OUTCOMES STATEMENT
Nurses attending this activity will be able to provide high quality care based on an enriched understanding of current research, emerging treatments and procedures related to mechanisms of heart transplant rejection, novel approaches to immunosuppression, and cases for tailoring vs customization of treatment. They will be able to identify at least one new learning related to innovations in the management of heart failure with mechanical support devices.

EDUCATION METHODS
Didactic lectures, panel discussion
EVALUATION METHOD
Evaluation by questionnaire will address program content, presentation, and possible bias.

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

**Physicians**
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 7.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Nurses**
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Houston Methodist will provide up to 7.5 contact hours for this activity. Participants must attend each session in its entirety and complete the corresponding items on the evaluation tool.

**Transplant Coordinators**
This course has been approved by the American Board for Transplant Certification for 7.75 Category I CEPTCs.

**Social Workers**
Houston Methodist and J.C. Walter Jr. Transplant Center designate this activity for 7.0 CEU for social work. This offering complies with section 781.509 of the rules of the Texas State Board of Social Work Examiners.

HOW TO RECEIVE YOUR CERTIFICATE

**Physicians**
An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

**Nurses**
To be awarded up to 7.5 contact hours for this continuing education activity, the participant must:
- Be sure to check in and complete the sign in process
- Attend each session in its entirety (Contact hours are awarded only for full day attendance)
- Complete the evaluation tool. An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.

Disclaimer and Disclosures
Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.
Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

All the relevant financial relationships listed for these individuals have been mitigated.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Relevant Financial Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arvind Bhimaraj, MD, MPH, FACC, FHFS A</td>
<td>Speaker/Moderator</td>
<td>Consultant: CareDx</td>
</tr>
<tr>
<td>Maryjane Farr, MD, MSc, FACC, FAST</td>
<td>Speaker</td>
<td>Planning (Steering Committee)-TransMedics</td>
</tr>
<tr>
<td>Ashrith Guha, MD, MPH FACC</td>
<td>Speaker/Planner</td>
<td>Speaker: Actelion; Bayer; Abbott; Consultant/Advisory Board: Cytokinetics</td>
</tr>
<tr>
<td>Shelley Hall, MD, FACC, FHFS A, FAST</td>
<td>Speaker/Moderator</td>
<td>Consultant/Advisor: Natera; CareDx; Abbott; Abiomed; Medtronic</td>
</tr>
<tr>
<td>Annette M Jackson, PhD, F(ACHI)</td>
<td>Speaker/Moderator</td>
<td>Consultant: Hansan BioPharma; Speaker: Novartis; Researcher: CareDx; Speaker: One Lambda</td>
</tr>
<tr>
<td>Marlena Habal, MD, FRCPC</td>
<td>Speaker/Moderator</td>
<td>Investigator: Bristol Myer Squibb</td>
</tr>
<tr>
<td>Ju Kim, MD, FACC</td>
<td>Moderator</td>
<td>Consultant: CareDx</td>
</tr>
</tbody>
</table>

All other individuals in control of content of this activity have no relevant financial relationships with ineligible companies to disclose.
EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors at this activity:

Astellas
CareDx
Takeda